- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
PacBio Adds David Meline to Board of Directors
Executive previously served as chief financial officer of Moderna, Amgen, and 3M.
PacBio, a developer of sequencing solutions, announced the appointment of David Meline to its board of directors. Before joining PacBio, Meline most recently worked as chief financial officer of Moderna. Before joining Moderna, he spent time in the same role for both Amgen and 3M between 2008 and 2020.
"I am thrilled to join the PacBio Board at this pivotal stage," said Meline. "I've dedicated the latter part of my career to leading healthcare organizations that leveraged the power of genomics to develop some of the most groundbreaking therapies, so naturally, PacBio's mission resonated with me. I believe the industry has only scratched the surface on how genomics can transform human health and am eager to help guide the company as it executes this mission."
Reference: PacBio Announces Appointment of David Meline to Board of Directors. PR Newswire. October 16, 2023. Accessed October 16, 2023. https://www.prnewswire.com/news-releases/pacbio-announces-appointment-of-david-meline-to-board-of-directors-301957110.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
